Newborns with vitamin D deficiency may face higher risk for schizophrenia later in life, a Danish case-control study indicated. “The next step is to conduct randomized clinical trials of vitamin D supplements in pregnant women who are vitamin D deficient, in order to examine the impact on child brain development and risk of neurodevelopmental disorders such as autism and schizophrenia,” said study author John McGrath, MD, PhD, of Queensland Brain Institute in Australia, in a statement. (Scientific Reports)
Instagram is cracking down on posts that promote eating disorders by expanding their list of unsearchable hashtags. (BBC)
Intravenous and oral ganaxolone succeeded in two phase II clinical trials for the treatment of postpartum depression, developer Marinus Pharmaceuticals announced. The Magnolia and Amaryllis studies demonstrated safety and efficacy, but the firm said more work is needed to optimize the dosing.
Younger siblings of children with attention-deficit hyperactivity disorder or autism spectrum disorder showed a substantially increased risk of developing these disorders themselves. (JAMA Pediatrics)
A cognitive behavior therapy app, reSET-O, was cleared by the FDA this week for treatment of opioid abuse, said Sandoz and Pear Therapeutics.
Researchers diagnosed James Bond with severe alcohol use disorder, as he met six of the 11 DSM-5 criteria for the disorder based on his behavior in 24 movies. (Medical Journal of Australia)
Contrary to popular belief, doing puzzles such as crosswords and Sudoku are unlikely in helping stave off cognitive decline and dementia later in life. (BMJ)
Updated guidelines in Pennsylvania now suggest limiting opioids prescribed for patients discharged from the emergency department to a 1-week supply. (The Philadelphia Tribune)
In related news, the FDA declined to approve Mallinckrodt’s abuse-deterrent oxycodone. (Reuters)